CTI BioPharma

CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CTI BioPharma Corp. a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin's lymphoma; Brostallicin, which is in a first-line Phase II study for the treatment of sarcoma; and OPAXIO, a chemotherapeutic agent for the potential treatment of non-small cell lung, ovarian, and other cancers. It has collaboration and licensing arrangements with Novartis International Pharmaceutical, Ltd.; and PG-TXL Company, L.P.

STOCKHOLM , June 26, 2023 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO:SOBI) and CTI BioPharma Corp. (NASDAQ:CTIC) (CTI) announced today the completion of the acquisition of CTI by Sobi through its indirect wholly owned subsidiary Cleopatra Acquisition Corp. (Cleopatra). Following the completion of Sobi's successful tender offer to purchase all outstanding shares of common stock of CTI for USD 9.10 per share in cash, net to the seller thereof in cash, without interest and subject to any applicable withholding taxes, Sobi acquired all remaining shares of common stock of CTI through a merger pursuant to Section 251(h) of the General Corporation Law of the State of Delaware.

Sobi completes acquisition of CTI BioPharma Corp.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION.

Sobi successfully completes tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CTI BioPharma Corp. (NasdaqCM: CTIC) to Swedish Orphan Biovitrum AB ("Sobi"). Under the terms of the proposed transaction, shareholders of CTI will receive only $9.10 in cash for each share of CTI that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate,.

CTI BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CTI BioPharma Corp. - CTIC

SEATTLE , May 30, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has cancelled the 2023 Annual Meeting of Stockholders (the "Annual Meeting") which was scheduled for June 21, 2023, and has withdrawn the proposals to have been submitted to stockholders at the Annual Meeting. The Annual Meeting has been cancelled due to the ongoing tender offer by Swedish Orphan Biovitrum AB (publ) (STO: SOBI) ("Sobi") to acquire all of the outstanding common stock of CTI pursuant to the Agreement and Plan of Merger, dated as of May 10, 2023, by and among Sobi, a Swedish public limited liability company, Cleopatra Acquisition Corp., a Delaware corporation and an indirect, wholly owned subsidiary of Sobi ("Purchaser"), and CTI (the "Merger Agreement").

CTI BioPharma Announces Cancellation of its 2023 Annual Meeting of Stockholders

Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

CTI BioPharma shares added almost 85% on the news that the company would be acquired by Stockholm-based hematology and immunology leader Swedish Orphan Biovitrum AB (Sobi). Seattle-based CTI is a biopharmaceutical company focused on the development and commercialization of novel therapies for blood-related cancers.

CTI BioPharma skyrockets on acquisition by Sobi

CTI BioPharma has one FDA-approved therapy, Vonjo, to treat a rare form of bone marrow cancer. The company is being bought at a 89% premium from its closing price on Tuesday.

Why Shares of CTI BioPharma Are Soaring Wednesday

CTI BioPharma, a Seattle-based publicly traded biotech company developing therapies for blood-related cancers, is set to be acquired in a deal with Swedish biotech giant Sobi.

Swedish drugmaker SOBI to acquire Seattle biotech giant CTI BioPharma for $1.7B

MILWAUKEE , May 10, 2023 /PRNewswire/ -- Ademi LLP is investigating CTI BioPharma (Nasdaq: CTIC) for possible breaches of fiduciary duty and other violations of law in its transaction with Sobi.  Click here to learn how to join the action https://www.ademilaw.com/case/cti-biopharma-corp or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether CTI BioPharma Corp. has obtained a Fair Price in its transaction with Sobi

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CTI BioPharma Corp. (NASDAQ: CTIC) to Swedish Orphan Biovitrum AB for $9.10 per share is fair to CTI BioPharma shareholders. Halper Sadeh encourages CTI BioPharma shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether.

CTIC STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of CTI BioPharma Corp. Is Fair to Shareholders

CTI BioPharma (NASDAQ: CTIC ) stock is taking off on Wednesday after the company announced a major acquisition deal with Sobi. This deal has Sobi agreeing to acquire CTI BioPharma for $1.7 billion.

Why Is CTI BioPharma (CTIC) Stock Up 85% Today?

Swedish Orphan Biovitrum will buy CTI for $9.10 a share as it looks to expand its rare hematology portfolio.

CTI BioPharma Soars After Agreeing $1.7 Billion Sale. Biotech Deals Keep Coming.

Rivian Automotive

Upstart Holdings

CTI BioPharma Corp. CTIC stock soared 83% in premarket trading after Swedish Orphan Biovitrum AB SE:SOBI said it had entered into an agreement to acquire the biotech in a deal valued at $1.7 billion. The offer represents a premium of 88.

CTI BioPharma soars on deal news, while Upstart and Rivian climb after earnings

Swedish Orphan Biovitrum AB SE:SOBI on Wednesday announced that it has entered into an agreement to acquire U.S.-based CTI BioPharma Corp. CTIC in a deal valued at $1.7 billion. The Stockholm-based drugmaker said it will offer $9.10 for each share of CTI, which focuses on blood-related cancers and rare diseases.

Swedish Orphan Biovitrum to acquire CTI BioPharma in a deal valued at $1.7 billion

Sobi to acquire CTI BioPharma Corp. enhancing Sobi's position in rare haematology

Transaction Price of $9.10 Per Share Represents Compelling 89% Premium to CTI's Closing Stock Price on May 9, 2023 SEATTLE , May 10, 2023 /PRNewswire/ -- CTI BioPharma (Nasdaq: CTIC) ("CTI"), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that it has entered into a definitive agreement under which Swedish Orphan Biovitrum AB (STO: SOBI) ("Sobi"), a global healthcare leader in hematology, immunology and specialty care, will acquire CTI for $9.10 per share of common stock in an all-cash transaction, representing an implied equity value of approximately $1.7 billion. The transaction will diversify Sobi's portfolio of leading hematology medicines through CTI's lead product, VONJO® (pacritinib), which is FDA-approved for the treatment of adult myelofibrosis patients with a platelet count below 50 x109/L.

Sobi to Acquire CTI BioPharma

SEATTLE , May 4, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but under the terms of the Amended and Restated 2017 Equity Incentive Plan) and material to the employee's acceptance of employment with the company. The equity award was approved on May 3, 2023, in accordance with Nasdaq Listing Rule 5635(c)(4).

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CTI BioPharma (CTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will CTI BioPharma (CTIC) Report Negative Earnings Next Week? What You Should Know

SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that its first quarter 2023 financial results will be reported on Thursday, May 11, 2023, after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m.

CTI BioPharma To Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

– Data presentation on spleen volume reduction in patients with myelofibrosis also accepted for poster discussion – SEATTLE , May 1, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that two abstracts have been accepted for presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL. Presentation details are as follows: Title: Spleen volume reduction (SVR) predicts overall survival (OS) in myelofibrosis (MF) patients on pacritinib (PAC) but not best available therapy (BAT): PERSIST-2 landmark OS analysis Abstract #:  7018 Presenter:  Helen Ajufo, M.D.

CTI BioPharma Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

VONJO Keeps CTI BioPharma A Buy

SEATTLE, Wash. , April 12, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted therapies for blood-related cancers, today announced that the management team will participate in two upcoming investor conferences in April 2023.

CTI BioPharma to Participate in Two Upcoming Investor Conferences in April 2023

Amylyx Pharmaceuticals

Apellis Pharma

Ascendis Pharma

Axsome Therapeutics

Cogint

IVERIC bio Inc

Mirati Therapeutics

Reata Pharmaceuticals

Seagen

David Kim is the founder and Chief Investment Officer of Ghost Tree Capital. Before founding Ghost Tree Capital in 2013, Kim worked as the portfolio manager at Diamondback Capital (Nov 2006 – Dec 2012).

These Are the Top 10 Holdings of David Kim

CTI BioPharma Corp. (NASDAQ:CTIC ) Q4 2022 Earnings Conference Call March 6, 2023 8:30 AM ET Company Participants Remy Bernarda – Investor Relations Adam Craig – President, Chief Executive Officer and Interim Chief Medical Officer David Kirske – Chief Financial Officer Jim Fong – Chief Commercial Officer Conference Call Participants Ken Shields – SVB Securities Ben Burnett – Stifel Gil Blum – Needham Reni Benjamin – JMP Securities Thomas Flaten – Lake Street Capital Markets Robert Hazlett – BTIG Operator Good morning, and welcome to the CTI BioPharma Fourth Quarter and Year-End 2022 Financial Results and Corporate Update Conference Call. As a reminder, this conference call is being recorded.

CTI BioPharma Corp. (CTIC) Q4 2022 Earnings Call Transcript

CTI BioPharma (CTIC) delivered earnings and revenue surprises of -55.56% and 15.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

News for CTI BioPharma Stock (CTIC)